Protalix BioTherapeutics Inc. (DE)
Last updated September 27, 2026
Organization details
- Legal name
- Protalix BioTherapeutics Inc. (DE)
- Ownership
- Public
- Status
- Active
- Headquarters country
- Israel
- Ticker symbol
- PLX
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001006281
Board of directors
-
Aharon Schwartz · DirectorSince 2023
-
Amos Bar-Shalev · DirectorSince 2023
-
Dror Bashan · Director · PRESIDENT AND CEOSince 2023
-
Eliot Forster · DirectorSince 2023
-
Gwen A. Melincoff · DirectorSince 2023
-
Pol F. Boudes · DirectorSince 2023
-
Zvi Shmuel Ben · DirectorSince 2023
Chief executives
Dror Bashan
· President and CEO
Dates unknown
Board connections
1 of this board's directors also sit on 2 other boards.
- via Gwen A. Melincoff
- via Gwen A. Melincoff
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 23, 2024 | Rubin Eyal Officer (Sr. VP and CFO) | Grant or award | +99,010 | — | — |
| Apr 1, 2024 | Dror Bashan Director, Officer (PRESIDENT AND CEO) | Grant or award | +263,960 | — | — |
| Oct 19, 2023 | Dror Bashan Director, Officer (PRESIDENT AND CEO) | Open-market purchase | +48,387 | $1.40 | $67,742 |
| Oct 19, 2023 | Dror Bashan Director, Officer (PRESIDENT AND CEO) | Open-market purchase | +16,129 | $1.41 | $22,742 |
| Aug 15, 2023 | Dror Bashan Director, Officer (President and CEO) | Grant or award | +800,000 | — | — |
| Aug 15, 2023 | Rubin Eyal Officer (Sr. VP and CFO) | Grant or award | +201,903 | — | — |
| Aug 15, 2023 | Hayon Yael Officer (VP, Research & Development) | Grant or award | +35,115 | — | — |
| Aug 15, 2023 | Naos Yaron Officer (Sr. VP, Operations) | Grant or award | +187,344 | — | — |
| Jan 3, 2023 | Aharon Schwartz Director | Open-market purchase | +110,000 | $1.42 | $156,200 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.